EUVIMEDEUVIMED entdecken
Crossref

Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome

Alexandra Zabeida iD, Jack J Brzezinski iD, Jonathan D Wasserman, Cheryl Cytrynbaum, Rosanna Weksberg, Kelley Zwicker, Kevin Zbuk, Alessandro Gasparetto iD, Laura Willis, Michelle Fantauzzi, Manuel Carcao

Pediatric Blood & Cancer · 2024-11 · 71 (11)

DOI: 10.1002/pbc.31282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 21.08.2024. Verfasst von Alexandra Zabeida und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Paediatric Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Cana…. Hauptthemen laut MEDLINE: Sirolimus, Hamartoma Syndrome, Multiple. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphatase and tensin homolog ( PTEN ) hamartoma tumor syndrome (PHTS) is a rare condition associated with vascular anomalies and increased tumor risk. Sirolimus, an mTOR inhibitor used for managing vascular anomalies is underexplored in PHTS. A single‐institution retrospective review of children with PHTS and vascular anomalies treated with sirolimus identified seven patients. Median age at sirolimus initiation was 10 years. After a median 2.5‐year follow‐up, six of seven patients (86%) showed significant clinical improvement. No significant adverse effects were observed, except mild buccal ulcers and acne. This study supports sirolimus as an effective and safe treatment for vascular anomalies in a small group of children with PHTS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusHamartoma Syndrome, MultipleHumansMaleFemaleChild, PreschoolChildAdolescentFollow-Up StudiesBlood Vessels

Stichwörter der Autor:innen

PTEN hamartoma tumor syndromechildsirolimusvascular anomalies

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Division of Paediatric Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Division of Endocrinology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Division of Community Pediatrics, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada.
  • Hamilton Health Sciences, Division of Medical Oncology, Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
  • Department of Diagnostic Imaging, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Alexandra Zabeida, Jack J Brzezinski, Alessandro Gasparetto

Zitieren

APA

Zabeida, A., Brzezinski, J. J., Wasserman, J. D., Cytrynbaum, C., Weksberg, R., Zwicker, K., Zbuk, K., Gasparetto, A., Willis, L., Fantauzzi, M., & Carcao, M. (2024). Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome. Pediatric Blood & Cancer, 71(11). https://doi.org/10.1002/pbc.31282

Vancouver

Zabeida A, Brzezinski JJ, Wasserman JD, Cytrynbaum C, Weksberg R, Zwicker K, et al. Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome. Pediatric Blood & Cancer. 2024;71(11). doi:10.1002/pbc.31282

BibTeX
@article{Zabeida2024,
  author = {Zabeida, Alexandra and Brzezinski, Jack J and Wasserman, Jonathan D and Cytrynbaum, Cheryl and Weksberg, Rosanna and Zwicker, Kelley and Zbuk, Kevin and Gasparetto, Alessandro and Willis, Laura and Fantauzzi, Michelle and Carcao, Manuel},
  title = {Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  volume = {71},
  number = {11},
  doi = {10.1002/pbc.31282}
}
Kostenlos starten →